~~<i id='93BBC8ABDF'><strike id='93BBC8ABDF'><tt id='93BBC8ABDF'><pre id='93BBC8ABDF'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：entertainment 2025-10-02 00:18:12 - browse：9472

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Just how do doctors, lawmakers, and the public define abortion?

hotspot

entertainment

hotspot

leisure time

focus

AdobeBothHumanaandCVSHealthonWednesdaytoutedplanstoaggressivelyscaletheirprimarycareclinicsforsenior

WSS

CDC marks new Covid

Headspace, Meta partner to launch VR meditation app for Quest

Influencer to be charged after chaos erupts in New York City's Union Square

What Henrietta Lacks settlement says about racism in medicine

Change Healthcare cyberattack prompts Medicare loan program

Former medical device CEO who sold dummy, plastic parts convicted of fraud

hotspot

Wikipedia

hotspot

Medical leaders decry Supreme Court decision on affirmative action

What it’s like to watch children die of measles

How to save PrEP access — and even expand it

A cyberattack has disrupted hospitals and health care in several states

After affirmative action ruling, medical educators look to 'holistic review'

OTC birth control: A brief history of over the counter pill design

Moonlake's readout produced a cash windfall. Risks remain

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

hotspot

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Humana, CVS hope to turn members into patients at clinics

Attacks on the drug industry will lead to fewer breakthroughs

UnitedHealth quietly bought dozens of outpatient centers

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Humana, CVS hope to turn members into patients at clinics

entertainment

hotspot

leisure time

focus